GlassScriptPhysician profile
Heather Nicole Marks
NPI 1366896342
$2,997.91
in general payments reported to CMS, 2019-2025
30 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $546 · 2023: $775 · 2024: $1,056 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.83 | 2021-2025 | |
| Novo Nordisk INC | $385.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $256.22 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $248.19 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $201.93 | 2021-2024 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $191.81 | 2022-2025 | Eliquis |
| Amgen INC. | $160.07 | 2021-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $153.04 | 2021-2024 | Veozah |
| Exact Sciences Corporation | $139.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.56 | 2022-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $110.43 | 2022-2025 | Trelegy Ellipta |
| Pfizer INC. | $86.01 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.02 | 2022 | |
| Dexcom, INC. | $59.56 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.29 | 2022-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $38.87 | 2023 | Keveyis |
| Alkermes, INC. | $31.12 | 2024 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $27.97 | 2022 | |
| Phathom Pharmaceuticals, INC. | $24.30 | 2024 | Voquezna |
| Boston Scientific Corporation | $21.99 | 2023 | Watchman Access System |
| Ardelyx, INC. | $18.13 | 2025 | Ibsrela |
| Eisai INC. | $18.12 | 2024 | |
| Merck Sharp & Dohme LLC | $16.73 | 2022 | |
| Lundbeck LLC | $16.07 | 2025 | Vyepti |
| Sumitomo Pharma America, INC. | $15.40 | 2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $15.38 | 2023 | |
| Sanofi Pasteur INC. | $14.96 | 2023 | |
| Mylan Specialty L.P. | $14.23 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $13.59 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.